Karyopharm reports preliminary FY2022 revenue ~$157.7M, extends cash runway to late 2025

Karyopharm Therapeutics Inc.

Preliminary FY2022 total revenue ~$157.7M; XPOVIO US net revenue ~$120.4M, up 22% YoY.
Q4 2022 total revenue ~$34.2M; XPOVIO US net revenue ~$31.1M.
Cash & investments ~$279.0M as of Dec 31, 2022, following $165M private placement; runway extended to late 2025.
Initiated Phase 3 EC-042 for selinexor in TP53 wild-type endometrial cancer; partnership with Foundation Medicine for companion Dx.
Planning to initiate Phase 3 MF study in 1H 2023; updated Phase 1 selinexor+ruxolitinib data in MF expected in 1H 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Karyopharm Therapeutics Inc. reported fourth quarter and full year 2022 results: revenue approximately $34.2 million for the fourth quarter 2022 and approximately $157.7 million for the full year 2022.

Period: fourth quarter and full year 2022
Revenue: approximately $34.2 million for the fourth quarter 2022 and approximately $157.7 million for the full year 2022
Result: preliminary results

Exact text from the filing

On January 9, 2023, Karyopharm Therapeutics Inc. (the “Company”) announced preliminary unaudited fourth quarter and full year 2022 total revenue and U.S. XPOVIO ® (selinexor) net product revenue estimates, and outlined its 2022 achievements and 2023 objectives.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-004183

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.